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Abstract 
BACKGROUND: Drug-mediated disruption of IL17A, IL17F, and IL17RA proteins 
is effective in psoriasis. However, disruption of the IL17 pathway by functional 
mutations has so far only been shown to affect risk in IL23R and TRAF3IP2. It is 
unclear if this is due to rarity of disruptive mutations. OBJECTIVE: (i) to delineate 
the prevalence of mutations in key IL17-pathway genes; (ii) to identify candidate 
regulatory sites acting on IL23R, IL17A, IL17RA, TRAF3IP2 from a distance. 
METHODS: Extraction of mutation frequencies from ExAc data, evolutionary 
sequence alignment; mapping of long-range-interacting (LRI) enhancers; genetic 
association testing in a novel psoriasis cohort. RESULTS: the prevalence of 
disruptive mutations in genes such as IL17RA is sufficient to have been 
detectable by existing datasets. Therefore, lack of their association with 
psoriasis indicates that genetic risk primarily resides in variants acting from a 
distance. We identify two LRI enhancer sites, regulating IL17RA and TRAF3IP2, 
respectively. The TRAF3IP2 regulator localises to the TRAF3IP2-antisense 
promoter, suggesting feedback-regulation. Both LRI sites are associated with 
psoriasis in a novel Scottish psoriasis cohort and the TRAF3IP2-LRI  at 
rs71562294 replicates in the WTCCC cohort. CONCLUSION: Genetic risk for 
psoriasis may be encoded at LRI sites regulating IL17 pathway genes from a 
distance. 
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Background 
Blocking the function of the proteins encoded by IL17A/F, IL17RA, and 
IL23R improves psoriasis. Accordingly, genetic associations between psoriasis 
and IL-17 pathway genes, including IL23R [1] and the key signal transducer 
TRAF3IP2 (also called ACT1) [2] have been reported. Nevertheless, the overall 
risk conferred by these variants remains moderate (mean OR 1.98 for IL23R and 
1.11 for TRAF3IP2, respectively [3]) and, despite acting as direct drug targets, 
no genetic association has been identified for IL17F, IL17A, or IL17RA. It 
remains unclear whether the frequency of disruptive mutations in these genes is 
too low to have been detectable by existing studies. Thus, present 
understanding of IL17 – pathway genetics in psoriasis does not account for the 
observation that close to 90% of patients show a major response to anti-IL17A or 
anti-IL17RA drugs [4-6]. 
Most disease-modifying variants do not reside in or near genes but 
instead in regulatory elements as far as 200 kb from the actual gene locus [7]. 
Such long-range-interaction (LRI)  variants have been mapped by as DNA-
hypersensitive sites (DHS), histone-marks indicating active transcriptional 
activity (H3K27Ac), or expression quantitative trait loci (eQTL). Although 
available databases do not fully represent key cell types driving psoriasis activity  
( T-cells, Th17 subsets, dermal fibroblasts), they do allow preliminary mapping 
of putative LRI sites. 
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Questions Addressed  
We here focussed on four key genes as follows: IL23R, IL17A, IL17RA as 
genes encoding direct drug targets and TRAF3IP2, since this gene exhibits the 
strongest genetic IL17 pathway association. 
Blocking the activity of proteins including IL23R, IL17A, IL17RA inhibits 
the psoriasis phenotype. Therefore, blocking the activity of these same proteins 
through naturally occuring mutations should affect an individuals’s risk and/or 
severity of being affected by psoriasis. However, this isn’t fully borne out by 
existing genetic association studies. We therefore addressed these questions: 
First, have such associations not been found because relevant mutations are too 
infrequent or because they locate to distal regulatory sites, having thus escaped 
mapping to their target genes? Second: can we identify candidate distal variants 
regulating IL23R, IL17A, IL17RA, and TRAF3IP2? Third: can we detect genetic 
association of such variants with psoriasis?  
 
Experimental Design 
Due to space constraints, all Methods have been placed into the 
Supplement (section ‘Supplementary Methods’). 
 
Results 
Disruptive IL17-pathway variants are common but not universally 
associated with psoriasis risk. A large Chinese exome study reported 
association of the variant Gly149Arg in the IL23R gene with psoriasis [8]. A 
GWAS analysis of a similarly sized Caucasian cohort did not replicate this, but 
instead reported association of another variant in the same gene 
(IL23R:p.Arg381Gln) [9]. Conversely, the latter study reported association of two 
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coding variants in the TRAF3IP2 gene not seen in the Chinese dataset [9]. By 
dataming of global exome variant data [10], we found that the Chinese and 
European datasets, respectively, detected those risk alleles most common in 
each population (Figure S3a), confirming that both datasets have sufficient 
statistical power to detect genetic associations of common variants (MAF > 0.1). 
Unexpectedly, we found that missense and loss-of-function (LOF) variants in 
IL17 pathway genes are in fact abundant in most global populations (Figure S3b, 
details in S1 datafile Exome Variants), and would have been detectable by the 
above-cited studies. Not all of these variants necessarily disrupt the gene 
product, but those likely to be deleterious can be identified by analyzing 
evolutionary protection. For example, more than 30 % of Europeans are carriers 
of the IL17RA:p.Ala691Thr missense mutation, which is 100 % conserved 
across a wide range of mammalian species (Figure S3c). The same goes for the 
IL17RA:p.Pro562Gln mutation, which is highly prevalent in East Asians (Figure 
S3c). In addition, Europeans, but not Asians exhibit two disruptive and 
evolutionary conserved mutations in IL17F that would have been detectable by 
[9] (Fig S3d). Of interest, the IL17A gene exhibits a notable scarcity of disruptive 
variants with the exception of one mutation relatively abundant in Hispanics, 
approximately 1%; (Fig. S3b). Independent of evolutionary protection, these 
mutations (exception: IL17F:p.Val155Ile) are predicted to be deleterious using 
the SIFT tool (http://sift.bii.a-star.edu.sg). Taken together, these data show that, 
while some variants directly disrupting IL23R and TRAF3IP2 do show the 
expected genetic association with psoriasis, many frequent IL17-pathway 
mutations do not. Therefore, genetic risk affecting psoriasis may reside in LRI 
sites acting from a distance.  
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A LRI site regulating IL17RA expression. In order to detect LRI sites, we 
mined available datasets for LRI regions, scanning 200 kb intervals around 
IL17A, IL17RA, IL23R, and TRAF3IP2. As shown in Figure 1A, we identified 
evidence for two LRI’s associated with IL17RA promoter activity in multiple cell 
lines based on CHIA-PET chromatin precipitation (labeled R1, R2, respectively). 
At higher resolution both R1 and R2 showed strong H3K27Ac histone marks as 
well as DNAse hypersenstivity, confirming active enhancer status (Figures 1B 
and 1C). Furthermore, both R1 and R2 contain SNPs independently identified as 
eQTL regulating IL17RA gene expression (see [11], for details S2 datafile eQTL). 
An additional independent eQTL dataset (GTex) also exhibits eQTL signals in 
R2, as well as an extensive cluster of eQTL signals within both R1 and R2 
(bottom of Figure 1B, 1C, respectively, complete GTex data in Figure S1). Taken 
together, several lines of evidence suggest that two novel LRI regions, localized 
approximatly 80 kb downstream of the IL17RA promoter within the CECR5 gene, 
regulate IL17RA expression. 
Long-range interaction of the TRAF3IP2-antisense promoter with 
TRAF3IP2. We also found strong evidence for LRI between the TRAF3IP2 
promoter and the TRAF3IP2-AS1 (antisense) promoter based on CHIA-PET 
(Figure 1D, region labelled “R3”). R3 is also highly enriched both for H3K27Ac 
and DHS marks (Figure 1E), consistent with active enhancer status. Again, two 
SNPs residing within R3, rs61269242 and rs1407644, have independently been 
identified as eQTL for TRAF3IP expression (S2 datafile eQTL). In further 
independent support, the TRAF3IP2 / TRAF3IP2-AS1 pair has been identified as 
a gene/natural-antisense pair in a recent study on breast cancer [12]. Taken 
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together, these data strongly suggest that TRAF3IP2 transcription is regulated 
by the abundance of its anti-sense product. 
Psoriasis cohort. In order to test association of these novel putative 
regulatory sites with psoriasis we assembled a discovery cohort based on a 
North-East Scottish demographic. The clinical characteristics of the cohort are 
shown in Table S3. The Tayside cohort represents a mix of approximately 75% 
HLA-Cw6+ and 25 % HLA-Cw6- patients. Accordingly, the majority of patients 
(67%) exhibit age at onset > 40 y. The cohort is also marked by a high median 
age (63y), and high female percentage (54%). In addition, it is heterogeneous in 
terms of prior treatment (half of patients naïve with respect to systemic 
treatments). Taken together, the Tayside/Scotland psoriasis cohort is distinct 
from previously reported cohorts, thereby broadening the genetic coverage of 
psoriasis. 
 Genetic associations of IL17-signalling variants. We initially performed a 
single-point association analysis of the Tayside cohort spanning 200 kb to either 
side of the transcriptional start site of each of the candidate genes. As shown in 
table S4, we replicated the strong association previously observed with 
TRAF3IP2. We also identified association with the eQTL rs71562294 mapping to 
the region R3 within the TRAF3IP2-antisense (AS1) promoter (Table 1, S2 
datafile eQTL). In addition, we identified two strongly associated SNPs located 
within 4 kb of the R1 LRI region regulating IL17RA (Table 1; Figure 1b marked 
by yellow lines and arrows). We did not detect association with the previously 
reported SNP rs11209026 at the IL23R gene locus [13]. We did identify 
significant association of SNPs in a putative enhancer 20kb upstream of IL17A 
which, however, only replicated in one out of three other cohorts (table S2, Fig. 
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S4) despite comparable allele frequencies (table S5), raising the possibility of an 
artifact. Thus, the present data identify novel associations at the distant IL17RA 
enhancer (R1) as well as a putative enhancer for TRAF3IP2 located 200 kb 
downstream TRAF3IP2-AS1 and confirm significant genetic association of single 
SNPs located within TRAF3IP2. 
 
Conclusion 
 
We here show that mutations disrupting IL17RA, IL17A, IL23R are 
common but do not necessarily affect psoriasis risk status, while drugs 
disrupting the proteins encoded by these same genes massively affect 
phenotype expression. This apparent paradox suggests that genetic risk for 
psoriasis may reside in LRI sites regulating these genes from a distance. 
We identify regions R1 and R2 as novel LRI enhancers for IL17RA. In line 
with these findings, two SNPs within 5-8 kb of R1 are associated with psoriasis 
in our novel discovery cohort. We also identify a novel LRI site located within the 
TRAF3IP2-AS1 promoter, 200 kb distant from the TRAF3IP2 promoter, showing 
genetic association with psoriasis both in our discovery cohort, as well as in the 
large WTCCC replication cohort. Given the identification of this site as an eQTL 
for TRAF3IP2 and the recent identification of the TRAF3IP-AS1 / TRAF3IP2 pair 
by [12], rs71562294 located within the TRAF3IP-AS1 promoter may well 
regulate TRAF3IP2 protein abundance. 
For IL17A itself, we observed a strikingly Th17-selective enhancer (Figure 
S2), which, in fact, exhibited association with psoriasis in the Scottish cohort, as 
well as a US-based replication cohort but not in additional replication cohorts 
(Results S1, S2). Comprehensive discovery of long-range interacting regions for 
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Th17 and -T cell specific genes including IL17A, IL17F, and IL23R will require 
DHS, histone, and eQTL data obtained in these cell types [14].  
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Table 1. Replication of LRI TRAF3IP2 regulating region association with psoriasis1   
  Scotland (Discovery) US UKBB 
(Replication 1) 
WTCCC (Replication 
2) 
Meta-analysis2 
GENE SNP OR p OR p OR p OR p 
TRAF3IP2 rs71562294 1.55 0.0043 1.14 0.39 1.62 1.0E-10 1.46 3.5E-04 
IL17RA rs1034858 0.75 0.0005 0.987 0.88 1.05 0.18 0.93 0.46 
IL17RA rs4819971 0.74 0.0005 0.989 0.89 1.05 0.19 0.92 0.45 
          
  Minor alle frequencies   
 allele cases controls cases controls cases controls   
rs71562294 G 0.089 0.059 
0.097 0.078 0.090 0.057 
  
rs1034858 C 0.389 0.460 
0.466 0.468 0.455 0.445 
  
rs4819971 T 0.389 0.460 
0.465 0.467 0.455 0.445 
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1OR- odds ratio, p- p-value. For details of the cohorts, see Methods. Size of replication cohort 1: 431 cases/ 838 controls; size of 
replication cohort 2: 2178 cases, 5175 controls. 
2Meta-analysis includes both discovery and replication cohorts, respectively. Both OR and P-values shown are for random models.
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Legends to Figures 
 
Figure 1. Long range interacting (LRI) regions connected with IL17RA and 
TRAF3IP2 promoter activity. A, LRI were identified from the WashU epigenome 
browser (epigenomegateway.wustl.edu/browser/). The curved lines indicate 
significant correlation of transcription factor binding, as measured by CHIA-PET, 
with the active expression of a gene in the cell types shown. Tracks exhibiting 
LRI to the IL17RA promoter in cell types relevant to psoriasis are shown in the 
figure. Genomic position is labelled according to Hg19. The light blue shaded 
box denotes the IL17RA transcriptional start site (TSS). B, close-up of the R1 
region, showing DNAse hypersensitive sites (black/grey bars), and histone 
H3K27Ac active enhancer marks (color code for each cell type: light blue: 
HUVEC; purple: NHEK, dark blue: K562, red: GM12878). eQTL marks linked to 
IL17RA expression at GTex are shown on the bottom (yellow dots with source 
tissue, respecively). The vertical arrows mark denote SNPs associated with 
psoriasis in the Tayside cohort (see Table S3). C, same as in B for region R2. D, 
LRI between the TRAF3IP2 promoter (light blue box on the right) and the 
TRAF3IP2-antisense (AS) promoter (marked R3). E, Close-up of the R3 region 
showing H3K27Ac enhancer as well as DNAse hypersensitivity marks. 
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